O Shaughnessy Asset Management LLC Invests $259,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

O Shaughnessy Asset Management LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,617 shares of the biopharmaceutical company's stock, valued at approximately $259,000.

Several other hedge funds and other institutional investors have also bought and sold shares of TGTX. Blue Trust Inc. increased its stake in shares of TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in shares of TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares during the period. Synergy Asset Management LLC bought a new position in shares of TG Therapeutics during the 4th quarter worth about $75,000. Finally, GAMMA Investing LLC increased its position in TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 2,171 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. HC Wainwright reissued a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Stock Down 0.6 %

Shares of TGTX traded down $0.23 during trading hours on Thursday, reaching $37.98. 349,308 shares of the stock traded hands, compared to its average volume of 3,105,394. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a fifty day simple moving average of $36.08 and a 200 day simple moving average of $31.64. The company has a market cap of $5.97 billion, a price-to-earnings ratio of -380.41 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. On average, equities analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.